We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lumos Pharma Inc | NASDAQ:LUMO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.34 | 4.32 | 4.20 | 0 | 00:00:00 |
NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed acquisition of the company by Double Point Ventures LLC. Stockholders will receive $4.25 and one contingent value right for each share of Lumos Pharma stock that they hold. The transaction is expected to close by the end of 2024.
If you are a stockholder of Lumos Pharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/lumo/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View original content:https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-lumos-pharma-inc-302284927.html
SOURCE Rowley Law PLLC
Copyright 2024 PR Newswire
1 Year Lumos Pharma Chart |
1 Month Lumos Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions